Treats cancer patients in outpatient clinics and at home with medical oncology and radiation therapy.
Jun 2026Revenue $587M/yrExpenses $613M/yr
Expected break-even Mar 2027
Figures by year
When will Starling Oncology be profitable?
Its revenue and expense trends are projected to cross in Mar 2027. In the 12 months to Jun 2026, revenue was $587M and expenses $613M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $503M | $539M | −$36.1M |
| Dec 2024 | $393M | $454M | −$60.1M |
| Dec 2023 | $324M | $401M | −$77.0M |
| Dec 2022 | $252M | $334M | −$82.0M |
| Dec 2021 | $203M | $249M | −$45.9M |
| Dec 2020 | $188M | $196M | −$8.20M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.